A tuftsin-derived peptide nasal spray approved in Russia since 2009 for anxiety—no sedation, no tolerance, no dependence, and almost no Western clinical data

Your immune system makes a protein fragment called tuftsin every time it breaks down antibodies—a four-amino-acid peptide (Thr-Lys-Pro-Arg) cleaved from the Fc region of IgG by enzymes in the spleen. Tuftsin's natural role is immune stimulation: it activates macrophages and enhances phagocytosis. But researchers at the Institute of Molecular Genetics in Moscow discovered something unexpected when they stabilized it—the resulting compound reduced anxiety.

Selank is that compound: tuftsin with a Pro-Gly-Pro tail added for metabolic stability, the same stabilization trick used on Semax (its "nootropic twin" from the same institute). Approved in Russia since 2009 as a 0.15% intranasal solution, Selank is prescribed for generalized anxiety, neurasthenia, and cognitive support. Its appeal is the safety profile—anxiolysis without the signature downsides of the two drug classes it competes with. It is not a benzodiazepine (no sedation, tolerance, or dependence). It is not an SSRI (no sexual dysfunction, weight gain, or discontinuation syndrome).

The evidence base mirrors Semax's editorial challenge. The mechanism is well-characterized, the animal data is extensive and consistent, and the Russian pharmaceutical approval implies controlled clinical trials—but those trials have not been published in English-language journals with sufficient detail for independent evaluation.

Quick Facts: Selank at a Glance

What Is Selank?

Pronunciation: SEH-lank

Every time your spleen breaks down an antibody, it releases a tiny peptide fragment called tuftsin—four amino acids (Thr-Lys-Pro-Arg) cleaved from the hinge region of immunoglobulin G by tuftsinylendocarboxypeptidase. In its natural role, tuftsin is an immunostimulant: it activates macrophages, enhances phagocytosis, and modulates cytokine release. People who lack tuftsin (after splenectomy, for example) are more susceptible to infections. Tuftsin is part of your immune system's housekeeping.

Selank is what happens when you stabilize tuftsin and discover that the result reduces anxiety. Researchers at the Institute of Molecular Genetics in Moscow added a C-terminal Pro-Gly-Pro sequence—the same stabilization platform used on Semax—and found that the resulting heptapeptide had robust anxiolytic properties in addition to tuftsin's known immune effects. This dual profile—anxiolytic and immunomodulatory—is unique in psychopharmacology.

The mechanism is multi-layered: Selank enhances GABA-A receptor sensitivity (the same receptor family that benzodiazepines target, but through an indirect mechanism), upregulates BDNF in the hippocampus and prefrontal cortex, modulates serotonin metabolism, inhibits enzymes that break down enkephalins (the body's natural painkillers), and retains partial tuftsin immunostimulatory activity. No other anxiolytic compound works through this combination of pathways.

Origins and Discovery

Selank was developed in the 1990s at the Institute of Molecular Genetics (IMG) of the Russian Academy of Sciences in Moscow by Nikolai Myasoedov's group—the same laboratory that developed Semax. The IMG had established the Pro-Gly-Pro platform as a general stabilization strategy for short bioactive peptides, and applied it to tuftsin as part of a broader program exploring the neurotropic potential of immune-derived peptides.

The discovery that tuftsin derivatives had anxiolytic properties was initially unexpected—tuftsin was known as an immune modulator, not a psychoactive peptide. But the observation was consistent with emerging evidence that immune system signaling molecules could influence brain function (the nascent field of psychoneuroimmunology). Selank became the first compound to bridge immune modulation and anxiolysis in a single molecule.

Russian pharmaceutical approval came in 2009 as a 0.15% intranasal solution for generalized anxiety disorder and neurasthenia (a Russian diagnostic category roughly equivalent to chronic fatigue with cognitive impairment). The approval was based on clinical trials conducted within the Russian regulatory framework, which, as with Semax, were not published in English-language journals with full methodological detail.

Mechanism of Action

GABAergic Modulation

Selank enhances GABA-A receptor sensitivity and increases GABA concentration in hippocampal neurons. Critically, this is indirect modulation—Selank does not directly bind the GABA-A receptor as benzodiazepines do. The distinction matters: direct GABA-A agonism causes sedation, tolerance, and dependence; indirect enhancement of GABAergic tone produces anxiolysis without those side effects. This pharmacological difference explains why Selank can reduce anxiety without causing the problems that limit benzodiazepine use (PMID 18421454).

BDNF Upregulation

Selank increases brain-derived neurotrophic factor (BDNF) expression in hippocampus and prefrontal cortex (PMID 18577377). BDNF promotes synaptic plasticity and neuronal resilience—effects that may contribute to both anxiolytic and nootropic properties. This mechanism overlaps with Semax, which also upregulates BDNF through a different upstream pathway.

Serotonin Metabolism

Selank modulates expression of genes involved in serotonin synthesis (TPH2) and transport (SERT). This suggests influence on serotonergic tone—relevant to both anxiety and mood regulation—though the mechanism is distinct from SSRIs, which directly block serotonin reuptake.

Enkephalin System Enhancement

Selank inhibits enzymes that degrade enkephalins—the body's endogenous opioid peptides involved in pain modulation and mood regulation. By increasing endogenous enkephalin levels (PMID 16454065), Selank may contribute to stress resilience and mood stabilization without directly activating opioid receptors.

Immunomodulation (Tuftsin Heritage)

Selank retains partial tuftsin immunostimulatory activity—enhanced phagocytosis, cytokine modulation, and immune cell activation (PMID 19904805). In human blood cells, Selank modulates expression of sixty-two genes involved in immune function. Whether the immune effects contribute to the anxiolytic properties (through neuro-immune crosstalk) or are simply a retained activity from the parent molecule remains an open question.

Key Research Areas and Studies

Anxiety Disorders

Zozulya et al. (2001, PMID 11517206) studied Selank in 62 patients with generalized anxiety disorder. The study reported anxiolytic efficacy—the most substantive English-language clinical evidence for Selank's primary indication. Russian Phase 2/3 trials supporting the 2009 approval presumably provide additional clinical data, but these are not available in English.

Cognitive Enhancement

Animal studies demonstrate improved performance on passive avoidance, Morris water maze, and recognition memory tasks (PMID 17476294). The cognitive enhancement mechanism likely involves BDNF upregulation and GABAergic optimization of hippocampal function—anxiety reduction and cognitive improvement are not independent effects.

Immunomodulation

Ershov et al. (2009, PMID 19904805) showed Selank modulates expression of cytokine and chemokine genes in human blood cells—confirming that the tuftsin-derived immune activity is retained in humans. This positions Selank uniquely among anxiolytics as a compound with dual neuro-immune activity.

Neuroprotection

Animal ischemia models show Selank provides neuroprotection comparable to Semax, though this indication has received less attention. The BDNF upregulation mechanism provides a biological basis for neuroprotective effects.

The Pro-Gly-Pro Platform—Two Drugs from One Trick

Selank and Semax represent a platform approach to peptide drug development that is unique in psychopharmacology. The Pro-Gly-Pro tripeptide tail was developed at the Institute of Molecular Genetics as a universal stabilization strategy for short bioactive peptides—and it worked on two completely different parent molecules to produce two complementary drugs.

Semax: ACTH(4-10) + Pro-Gly-Pro → nootropic/neuroprotective (cognition, BDNF, melanocortin) Selank: Tuftsin + Pro-Gly-Pro → anxiolytic/immunomodulatory (anxiety, GABA, enkephalin, immune)

The shared tail means both compounds have similar pharmacokinetic properties—similar half-lives (~15-30 minutes), similar intranasal delivery characteristics, and similar metabolic stability. But the biological activities are determined by the N-terminal bioactive fragment, not the tail. This is elegant pharmacological engineering: one stabilization technology, two distinct therapeutic profiles.

The community often combines Semax and Selank for "nootropic + anxiolytic" effects—the peptide equivalent of combining a cognitive enhancer with an anxiolytic. This combination has not been formally tested, but the distinct mechanisms suggest pharmacological compatibility.

Claims vs. Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

Zozulya et al. (2001) — GAD Clinical Study

Design: Clinical study. N=62 patients with generalized anxiety disorder. PMID 11517206.

Findings: Selank demonstrated anxiolytic efficacy in patients with GAD. This is the most substantive English-language clinical report for Selank and the primary basis for evaluating the clinical claim.

Limitations: Study design details (randomization, blinding, placebo control) are limited in the English-language report. N=62 is a meaningful sample for a Phase 2 study but insufficient for definitive efficacy claims.

Ershov et al. (2009) — Immunomodulatory Effects in Humans

Design: Human interventional study. N=20. Selank administration with blood cell gene expression analysis. PMID 19904805.

Findings: Selank modulated expression of sixty-two genes involved in immune function, including cytokines and chemokines. Confirms that Selank has measurable biological activity in humans—but this is a mechanistic study, not an efficacy trial for anxiety.

Russian Pharmaceutical Approval Data (2009)

The approval of Selank as a 0.15% anxiolytic nasal spray implies Phase 2/3 clinical trials were conducted. These data have not been published in English-language journals. The approval exists; the supporting data cannot be independently verified.

What Is Missing

No Western-standard, placebo-controlled, randomized trial specifically testing Selank for anxiety has been published in English. The human evidence consists of one clinical study (Zozulya) and one mechanistic study (Ershov). For a compound approved as an anxiolytic drug for sixteen years, this publication gap is striking.

Safety, Risks, and Limitations

Clean Safety Profile

Sixteen years of Russian pharmaceutical use without reported serious safety signals. Animal studies show no sedation, motor impairment, or cognitive blunting at anxiolytic doses. No tolerance development. No dependence or withdrawal.

No Known Sedation

This is Selank's primary safety differentiator from benzodiazepines. Indirect GABAergic modulation does not cause the CNS depression that direct GABA-A agonism produces.

Immunostimulatory Caution

Selank retains tuftsin's immunostimulatory activity. In healthy individuals, immune modulation may be neutral or beneficial. In autoimmune conditions, immune stimulation could theoretically worsen symptoms. No clinical data addresses this concern, but it is biologically plausible.

Nasal Irritation

Mild nasal irritation is the most commonly reported side effect from intranasal use.

No Drug Interaction Data

No formal drug interaction studies have been conducted to Western standards. The serotonergic modulation (TPH2/SERT effects) raises a theoretical question about interactions with SSRIs or other serotonergic drugs, though no cases of serotonin syndrome have been reported.

Legal and Regulatory Status

Russia: Approved prescription pharmaceutical since 2009. 0.15% intranasal solution for generalized anxiety and neurasthenia.

United States: Not approved. Not submitted. Legal status is research chemical.

European Union: Not approved. No EMA submission.

Research Protocols and Formulation Considerations

Approved Formulation (Russia)

• 0.15% Selank nasal drops: 1.5 mg/mL solution
• Typical dosing: 2-3 drops per nostril (approximately 300-450 mcg per dose), 3 times daily
• Supplied in small dropper bottles (3 mL)

Stability

The Pro-Gly-Pro tail extends the functional half-life to ~15-20 minutes. Intranasal delivery provides direct CNS access via olfactory pathways. Refrigeration recommended for storage.

Dosing in Published Research

All published clinical data on Selank uses intranasal delivery—the route for which it was developed and approved in Russia. The standard pharmaceutical formulation is a 0.15% nasal spray solution, dosed three times daily in 14-day courses. No Western dose-ranging, pharmacokinetic, or bioavailability studies have been published. The table below summarizes dosing from Russian pharmaceutical prescribing information and the limited published clinical studies.

Published Clinical Dosing

Key Points

• Russian approved dosing is intranasal: ~300-450 mcg per dose, 3 times daily, in 14-day courses
• Courses are typically followed by rest periods before repeating
• No Western dose-ranging or pharmacokinetic studies have been published

Dosing in Self-Experimentation Communities

Selank is widely used in the Western peptide community for anxiety management and stress reduction. Community protocols generally follow the Russian approved dosing: intranasal delivery, 300-450 mcg per dose, 2-3 times daily, in cycles.

Some community members use subcutaneous injection (100-300 mcg per dose), though all published clinical data uses the intranasal route. Selank and Semax are frequently combined by community users for complementary anxiolytic + nootropic effects.

This section reports community practices for informational purposes. These protocols have not been validated in Western clinical trials.

Combination Stacks

Research into Selank combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Selank with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

Selank is a genuinely novel anxiolytic—a peptide built from an immune fragment that reduces anxiety through pathways no other drug uses. Its multi-layered mechanism (indirect GABAergic modulation, BDNF upregulation, enkephalin enhancement, immunomodulation) is well-characterized in animal models. Its safety profile is clean: no sedation, no tolerance, no dependence—the trifecta that benzodiazepines fail.

Russian pharmaceutical approval since 2009 gives it a credibility that most peptide anxiolytics lack. Sixteen years of clinical use without serious safety signals is meaningful data, even if we cannot independently audit the underlying trials.

The limitation is the same one that affects Semax: the human clinical evidence base is thin in English. One clinical study (N=62) and one mechanistic study (N=20) are insufficient to definitively establish efficacy by Western standards. The evidence gap is one of publication and accessibility, not necessarily of absence—but the distinction matters less than you might think. What cannot be verified cannot be relied upon.

Verdict Recapitulation

Selank earns Reasonable Bet because it has a unique, well-characterized mechanism, consistent preclinical evidence, genuine pharmaceutical approval, and a safety profile that solves the central problem of anxiolytic pharmacology. The evidence gap is real but may reflect publication barriers rather than absence of data. Among peptide anxiolytics, Selank has the most coherent evidence-to-claim alignment.

For readers considering Selank, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Selank

Further Reading and Resources

If you want to go deeper on Selank, the evidence landscape for cognitive & neuroprotective peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Cognitive & Neuroprotective Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Selank — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Zozulya AA, Sizov SV, Tsagareli MG, et al. "Selank (TP-7): a nootropic and anxiolytic peptide for the treatment of anxiety disorders." Anxiety Disorders, 15(1), 17–28 (2001). PMID 11517206
2. Ershov FI, Uchakin PN, Uchakina ON, et al. "Selank modulates gene expression of chemokines and cytokines in human blood cells." Doklady Biological Sciences, 429(1), 543–545 (2009). PMID 19904805
3. Seredenin SB, Kozlovskaya MM. "Selank pharmacology: overview of the mechanisms of action and clinical applications." Eksperimental'naya i Klinicheskaya Farmakologiya, 75(8), 3–8 (2012)
4. Agapova TYu, Agniullin YV, Silachev DN, et al. "Selank effect on BDNF expression in rat hippocampus." Bulletin of Experimental Biology and Medicine, 145(6), 729–731 (2008). PMID 18577377
5. Kozlov SV, Grigor'ev VV, Kudrin VS, et al. "Anxiolytic-like effects of Selank in the elevated plus maze and conflict tests." Bulletin of Experimental Biology and Medicine, 145(4), 471–474 (2008). PMID 18421454
6. Kost NV, Sokolov OY, Kurasova OB, et al. "Inhibition of enkephalin-degrading enzymes by Selank: a possible mechanism of anxiolytic action." Bulletin of Experimental Biology and Medicine, 141(1), 77–80 (2006). PMID 16454065
7. Narkevich VB, Kudrin VS, Klodt PM, et al. "Effects of Selank on the content of monoamines and their metabolites in the brain of BALB/C and C57BL/6 mice." Eksperimental'naya i Klinicheskaya Farmakologiya, 70(1), 8–12 (2007). PMID 17476294
8. Lafon-Cazal M, Costentin J. "Tuftsin: history, biochemistry, and pharmacology." Peptides, 25(3), 1491–1503 (2004). PMID 15063783

---